ICLR vs. MEDP, CRL, INCY, IQV, CAH, ZBH, RMD, ALGN, BIIB, and ARGX
Should you be buying ICON Public stock or one of its competitors? The main competitors of ICON Public include Medpace (MEDP), Charles River Laboratories International (CRL), Incyte (INCY), IQVIA (IQV), Cardinal Health (CAH), Zimmer Biomet (ZBH), ResMed (RMD), Align Technology (ALGN), Biogen (BIIB), and argenx (ARGX). These companies are all part of the "medical" sector.
Medpace (NASDAQ:MEDP) and ICON Public (NASDAQ:ICLR) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.6% of ICON Public shares are owned by institutional investors. 20.3% of Medpace shares are owned by insiders. Comparatively, 44.0% of ICON Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Medpace has a net margin of 15.92% compared to Medpace's net margin of 8.30%. ICON Public's return on equity of 59.74% beat Medpace's return on equity.
Medpace has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, ICON Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.
ICON Public received 258 more outperform votes than Medpace when rated by MarketBeat users. Likewise, 64.99% of users gave ICON Public an outperform vote while only 64.00% of users gave Medpace an outperform vote.
Medpace presently has a consensus price target of $443.00, indicating a potential upside of 11.89%. ICON Public has a consensus price target of $327.50, indicating a potential upside of 6.22%. Given ICON Public's higher possible upside, equities analysts clearly believe Medpace is more favorable than ICON Public.
ICON Public has higher revenue and earnings than Medpace. ICON Public is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medpace had 27 more articles in the media than ICON Public. MarketBeat recorded 46 mentions for Medpace and 19 mentions for ICON Public. ICON Public's average media sentiment score of 0.60 beat Medpace's score of 0.51 indicating that Medpace is being referred to more favorably in the media.
Summary
Medpace beats ICON Public on 10 of the 18 factors compared between the two stocks.
Get ICON Public News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ICON Public Competitors List
Related Companies and Tools
